{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:40:45Z","timestamp":1782337245341,"version":"3.54.5"},"reference-count":26,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"National Cancer Institute Division of Cancer Epidemiology and Genetics","doi-asserted-by":"publisher","award":["5K08 CA255426-03"],"award-info":[{"award-number":["5K08 CA255426-03"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"National Cancer Institute Division of Cancer Epidemiology and Genetics","doi-asserted-by":"publisher","award":["P01 CA111412"],"award-info":[{"award-number":["P01 CA111412"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011541","name":"National Cancer Institute Division of Cancer Epidemiology and Genetics","doi-asserted-by":"publisher","award":["P01 CA65493"],"award-info":[{"award-number":["P01 CA65493"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jtct.2024.09.023","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T02:57:43Z","timestamp":1727751463000},"page":"1206.e1-1206.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["N-803, an IL-15 Superagonist Complex as Maintenance Therapy After Allogeneic Donor Stem Cell Transplant for Acute Myeloid Leukemia or Myelodysplastic Syndrome; A Phase 2 Trial"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4433-0127","authenticated-orcid":false,"given":"Aimee","family":"Merino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1997-3799","authenticated-orcid":false,"given":"Claudio C.","family":"Brunstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Shanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faridullah","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5140-4839","authenticated-orcid":false,"given":"Rose","family":"Wangen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Bachanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Juckett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1732-6694","authenticated-orcid":false,"given":"Joseph","family":"Maakaron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5945-0634","authenticated-orcid":false,"given":"Martin","family":"Felices","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8078-8579","authenticated-orcid":false,"given":"Daniel","family":"Weisdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0339-4944","authenticated-orcid":false,"given":"Jeffrey S.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jtct.2024.09.023_bib0001","doi-asserted-by":"crossref","first-page":"771.e1","DOI":"10.1016\/j.jtct.2021.05.011","article-title":"Relapse after allogeneic stem cell transplantation of acute myelogenous leukemia and myelodysplastic syndrome and the importance of second cellular therapy","volume":"27","author":"Zuanelli Brambilla","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.jtct.2024.09.023_bib0002","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1365-2141.2010.08409.x","article-title":"Lymphocyte subset reconstitution after unrelated cord blood or bone marrow transplantation in children","volume":"152","author":"Renard","year":"2011","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.jtct.2024.09.023_bib0003","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/bmt.2012.176","article-title":"Reconstitution of maturating and regulatory lymphocyte subsets after cord blood and BMT in children","volume":"48","author":"Charrier","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2024.09.023_bib0004","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/bloodadvances.2016000158","article-title":"Fewer circulating natural killer cells 28 days after double cord blood transplantation predicts inferior survival and IL-15 response","volume":"1","author":"Bergerson","year":"2016","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jtct.2024.09.023_bib0005","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/ijc.2910160204","article-title":"Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity","volume":"16","author":"Herberman","year":"1975","journal-title":"Int J Cancer"},{"issue":"8","key":"10.1016\/j.jtct.2024.09.023_bib0006","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.jtct.2024.09.023_bib0007","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1182\/blood-2013-10-532531","article-title":"Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein","volume":"123","author":"Bachanova","year":"2014","journal-title":"Blood"},{"issue":"357","key":"10.1016\/j.jtct.2024.09.023_bib0008","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.jtct.2024.09.023_bib0009","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1084\/jem.191.5.771","article-title":"Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice","volume":"191","author":"Kennedy","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.jtct.2024.09.023_bib0010","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1146\/annurev.immunol.14.1.179","article-title":"The interleukin-2 receptor gamma chain: its role in the multiple cytokine receptor complexes and T cell development in XSCID","volume":"14","author":"Sugamura","year":"1996","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"10.1016\/j.jtct.2024.09.023_bib0011","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nri1901","article-title":"The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design","volume":"6","author":"Waldmann","year":"2006","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"10.1016\/j.jtct.2024.09.023_bib0012","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1172\/JCI90387","article-title":"CD56bright NK cells exhibit potent antitumor responses following IL-15 priming","volume":"127","author":"Wagner","year":"2017","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.jtct.2024.09.023_bib0013","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2024.09.023_bib0014","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1074-7613(02)00429-6","article-title":"IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells","volume":"17","author":"Dubois","year":"2002","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.jtct.2024.09.023_bib0015","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.cyto.2011.09.028","article-title":"IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization","volume":"56","author":"Han","year":"2011","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.jtct.2024.09.023_bib0016","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1158\/2326-6066.CIR-15-0093-T","article-title":"Comparison of the superagonist complex, ALT-803, to IL15 as cancer immunotherapeutics in animal models","volume":"4","author":"Rhode","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"23","key":"10.1016\/j.jtct.2024.09.023_bib0017","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood-2017-12-823757","article-title":"First-in-human Phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation","volume":"131","author":"Romee","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.09.023_bib0018","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.3389\/fimmu.2018.02040","article-title":"NKG2D ligands-critical targets for cancer immune escape and therapy","volume":"9","author":"Schmiedel","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jtct.2024.09.023_bib0019","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bbmt.2018.07.038","article-title":"Reduced-intensity conditioning followed by related and unrelated allografts for hematologic malignancies: expanded analysis and long-term follow-up","volume":"25","author":"Warlick","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2024.09.023_bib0020","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1182\/blood.V80.9.2221.2221","article-title":"Role of monocytes in the expansion of human activated natural killer cells","volume":"80","author":"Miller","year":"1992","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2024.09.023_bib0021","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.3324\/haematol.2017.186619","article-title":"The early expansion of anergic NKG2A(pos)\/CD56(dim)\/CD16(neg) natural killer represents a therapeutic target in haploidentical hematopoietic stem cell transplantation","volume":"103","author":"Roberto","year":"2018","journal-title":"Haematologica"},{"issue":"13","key":"10.1016\/j.jtct.2024.09.023_bib0022","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood-2009-07-229740","article-title":"NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation","volume":"115","author":"Bjorklund","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2024.09.023_bib0023","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2011-06-364265","article-title":"Risk factors for acute GVHD and survival after hematopoietic cell transplantation","volume":"119","author":"Jagasia","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2024.09.023_bib0024","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJM199501193320303","article-title":"Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy","volume":"332","author":"Mackall","year":"1995","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2024.09.023_bib0025","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1912885","article-title":"Safety, tolerability, and long-term clinical outcomes of an IL-15 analogue (N-803) admixed with Bacillus Calmette-Guerin (BCG) for the treatment of bladder cancer","volume":"10","author":"Rosser","year":"2021","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.jtct.2024.09.023_bib0026","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2016-07-686642","article-title":"Classification systems for chronic graft-versus-host disease","volume":"129","author":"Lee","year":"2017","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724006912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724006912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T03:49:33Z","timestamp":1764560973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724006912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2666636724006912"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.09.023","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"N-803, an IL-15 Superagonist Complex as Maintenance Therapy After Allogeneic Donor Stem Cell Transplant for Acute Myeloid Leukemia or Myelodysplastic Syndrome; A Phase 2 Trial","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.09.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}